Lunate Capital Ltd Acquires Shares of 2,124,143 Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Lunate Capital Ltd bought a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,124,143 shares of the company's stock, valued at approximately $2,124,000. Neumora Therapeutics comprises about 1.2% of Lunate Capital Ltd's investment portfolio, making the stock its 4th biggest holding. Lunate Capital Ltd owned approximately 1.31% of Neumora Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. acquired a new position in Neumora Therapeutics in the fourth quarter valued at $64,000. Quantbot Technologies LP purchased a new position in shares of Neumora Therapeutics in the 4th quarter worth about $92,000. PEAK6 LLC purchased a new position in shares of Neumora Therapeutics in the 4th quarter worth about $117,000. EntryPoint Capital LLC acquired a new position in shares of Neumora Therapeutics in the 4th quarter valued at about $135,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Neumora Therapeutics during the 4th quarter worth about $143,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. William Blair downgraded Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, March 10th. Bank of America reiterated an "underperform" rating and issued a $1.00 target price (down previously from $7.00) on shares of Neumora Therapeutics in a research note on Wednesday, April 2nd. Royal Bank Of Canada reissued a "sector perform" rating and set a $4.00 price target on shares of Neumora Therapeutics in a research report on Tuesday, March 4th. Needham & Company LLC reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday, May 13th. Finally, HC Wainwright reduced their target price on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Neumora Therapeutics has a consensus rating of "Hold" and an average target price of $9.29.

Neumora Therapeutics Price Performance

NMRA traded down $0.01 on Wednesday, reaching $0.78. The company's stock had a trading volume of 1,132,601 shares, compared to its average volume of 1,525,347. Neumora Therapeutics, Inc. has a 1 year low of $0.61 and a 1 year high of $17.19. The business's 50 day moving average is $0.76 and its 200 day moving average is $2.09. The stock has a market cap of $126.52 million, a price-to-earnings ratio of -0.49 and a beta of 2.75.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.02). As a group, research analysts forecast that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.